Group 1: Reviva Pharmaceuticals Holdings, Inc. (RVPH) - RVPH is a clinical-stage biopharmaceutical company focused on therapies for central nervous system, respiratory, and metabolic diseases [1] - The current trading price is $0.44, with a target price of $0.39, indicating a potential downside of approximately -11.09% [1] - The significant gap between the current and target price suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage [1] Group 2: PDS Biotechnology Corporation (PDSB) - PDSB is trading at $0.93, with a discounted cash flow (DCF) valuation of $0.54, resulting in a price percentage difference of -41.72% [2] - The market cap of PDSB is $43.63 million, and it has an earnings per share (EPS) of -0.91, with a negative price-to-earnings (P/E) ratio of -1.58 [2] - This reflects the company's current unprofitability [2] Group 3: IO Biotech, Inc. (IOBT) - IOBT has a current stock price of $1.17 and a DCF valuation of $0.88, leading to a price percentage difference of -24.60% [3] - The market cap of IOBT is $77.08 million, with an EPS of -1.58 and a P/E ratio of -0.63 [3] - This indicates that IOBT is also trading above its intrinsic value, similar to PDSB, but with a slightly better valuation [3] Group 4: Skye Bioscience, Inc. (SKYE) - SKYE has a current stock price of $1.47 and a DCF valuation of $1.86, resulting in a positive price percentage difference of 26.28% [4] - The market cap of SKYE is $45.71 million, with an EPS of -1.06 and a P/E ratio of -3.89 [4] - This suggests that SKYE is undervalued compared to its intrinsic value, indicating potential growth despite current losses [4]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][4] - The company will participate in a fireside chat and KOL webinar on October 10, 2025, featuring discussions on schizophrenia treatment and clinical data for its lead drug candidate, brilaroxazine [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4]

Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Shares of Actelis Networks Inc (NASDAQ:ASNS) rose sharply in pre-market trading after the company announced a new contract.The contract value equals approximately 5.45% of the company’s current market capitalization. The networking solutions provider from Fremont, California, announced on Wednesday that it had secured around $0.3 million in orders for software and services from a major telecommunications carrier in Southern Europe, which is part of a global telecom group.Actelis Networks shares jumped 40.8% ...

Group 1: Reviva Pharmaceuticals Holdings Inc. (RVPH) - RVPH experienced a significant after-hours rally, increasing 18.27% to $0.58 after a 35.1% surge during regular trading, with a trading volume of over 40.5 million shares, nearly nine times its daily average [2][3] - The company has a market cap of $47 million and is focused on its lead candidate brilaroxazine, which targets neuropsychiatric and respiratory conditions [3] Group 2: Penumbra Inc. (PEN) - PEN surged 7.97% in after-hours trading to $273.69, following a 1.55% gain during the regular session, with a market cap nearing $9.9 billion [4][5] - The company has increased its revenue guidance for FY25 to a range of $1.355 billion - $1.370 billion, indicating a growth of 13% to 15% over 2024 [6] Group 3: Palisade Bio Inc. (PALI) - PALI jumped 10% in after-hours trading to $1.87, extending a 29.8% surge during the regular session, driven by a $138 million public offering [7][8] - The company has a market cap of $15.8 million and is gaining attention due to recent clinical updates and licensing agreements [8] Group 4: IO Biotech Inc. (IOBT) - IOBT rose 5.08% in after-hours trading to $0.4571, following a 22.3% surge during the regular session, with heavy trading volume of 16.7 million shares [9] - The company announced plans to design a new registrational study for its cancer vaccine candidate Cylembio after receiving regulatory feedback from the FDA [10] Group 5: Rallybio Corp. (RLYB) - RLYB increased 11.2% in after-hours trading to $0.5688, reversing a modest dip during the regular session, with a market cap of $21.4 million [11][12] - The company recently completed dosing in its Phase 1 study for RLYB116 and received a $12.5 million milestone payment for progress on the REV102 program [12] Group 6: Vor Biopharma Inc. (VOR) - VOR rose 3.6% in after-hours trading to $38.00, recovering from a 6.6% decline during the regular session, with a market cap of $251 million [13][14] - The company is focusing on its trem-cel platform and CD33-directed therapies for acute myeloid leukemia, alongside new executive appointments [14]

CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual Roth Healthc ...

Core Insights - Biotech stocks experienced strong after-hours gains, driven by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing [1] Group 1: Ovid Therapeutics Inc. (OVID) - Ovid Therapeutics saw a 7.69% increase in after-hours trading, reaching $1.40 after a regular session decline of 7.14% to $1.30 [2] - The stock's regular session selloff was marked by elevated trading volume of over 2.93 million shares, significantly above the average of 2.07 million shares [2] - Recent coverage from Lucid Capital initiated a Buy rating with a price target of $5.50, highlighting Ovid's pipeline assets in Phase 1 trials for drug-resistant epilepsies [3] Group 2: NeuroOne Medical Technologies Corp. (NMTC) - NeuroOne Medical Technologies rose 6.98% in after-hours trading to $0.9506 after a modest decline of 1.27% during the regular session [4] - The trading volume was relatively light at 134,720 shares, below the average of 315,000 shares [4] - The company announced a virtual roadshow webinar scheduled for October 7 to discuss operations and recent FDA clearance [5] Group 3: PepGen Inc. (PEPG) - PepGen experienced a 3.03% rise in after-hours trading, reaching $4.76 after closing at $4.62 [6] - The stock has surged over 120% in the past week due to positive clinical and financial updates [6] - A recent $100 million public offering was completed, expected to support the development of PGN-EDODM1 and PGN-EDO51 [9] Group 4: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals rose 5.81% in after-hours trading to $0.3900 after a 19.56% surge during the regular session [10] - The trading volume was significantly elevated at over 26 million shares, well above the average of 3.9 million shares [10] - The company recently announced a $9 million public offering priced at $0.30 per share [11] Group 5: Anika Therapeutics Inc. (ANIK) - Anika Therapeutics saw a 5.53% increase in after-hours trading, reaching $9.92 after closing at $9.40 [11] - The stock's regular session strength followed a quiet news cycle, with no new filings or press releases [12] - Anika is in focus ahead of its scheduled earnings report on October 30, 2025 [12]

Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) 2025 Conference September 30, 2025 10:15 AM ET Speaker0Hello, everyone, and thank you all for joining us during the Lithium Partners fall twenty twenty five investor conference. My name is Ben Shamsi. I'm vice president at Lithium Partners. During this fireside chat webcast, we welcome Revival Pharmaceuticals, ticker symbol RVPH on the Nasdaq. Joining us today is the company's CEO, doctor Lak Spa.Also joining us today is Mubalan Pachyapanam, senior research an ...

Core Insights - After-hours trading in the biotech and therapeutics sector saw significant price movements, particularly among small- and mid-cap companies, driven by clinical updates and strategic announcements [1] Company Summaries - **Cyclerion Therapeutics, Inc. (CYCN)**: Shares surged 48.01% to $4.47 after announcing a strategic relaunch focused on neuropsychiatric therapies, including a licensing agreement with MIT for its treatment-resistant depression program. The stock had closed at $3.02, down 0.66% during regular trading. A Phase 2 trial for the TRD program is expected to start in 2026, with initial data anticipated in 2027 [2][3] - **Clearside Biomedical Inc. (CLSD)**: The stock rose 6.82% to $4.23 after a regular session close of $3.96, despite a 9.79% decline during the day. The increase followed presentations at the EURETINA Congress regarding its Phase 2b ODYSSEY trial for wet age-related macular degeneration. The next key catalyst is the initiation of the Phase 3 trial, incorporating FDA feedback [3][4] - **Reviva Pharmaceuticals Holdings Inc. (RVPH)**: Shares increased by 11.50% to $0.32 after closing at $0.287, following a 6.61% decline during regular trading. The price action comes ahead of the company's participation in the Lytham Partners Fall 2025 Investor Conference [4][5] - **Acumen Pharmaceuticals, Inc. (ABOS)**: The stock advanced 5.69% to $1.30 after a regular session close of $1.23, despite a 3.91% decline during the day. The company reported that topline data from its Phase 2 ALTITUDE-AD trial is on track for late 2026 and plans to decide on advancing a preclinical candidate in early 2026 [5][6] - **PepGen Inc. (PEPG)**: Shares rose 5.13% to $2.05 after closing at $1.95, following an 8.02% decline during the day. The company completed patient dosing in its Phase 1 FREEDOM-DM1 trial and is on track to report topline data in early Q4 2025 [6][7] - **Corcept Therapeutics Inc. (CORT)**: The stock gained 4.54% to $87.10 after a regular session close of $83.32. The company announced it will present late-breaking data from its Phase 3 ROSELLA trial at the 2025 ESMO Annual Meeting. Two upcoming PDUFA dates were confirmed for relacorilant in hypercortisolism and platinum-resistant ovarian cancer [7][8][9]

CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference, ...